Sovereign Health's Flagship Treatment Center Gets New Clinical Director
Our program offers a multidisciplinary team that provides an intensive, practical, dual diagnostic treatment modality at our center, to increase harmony and understanding between the patient, family members, friends and community. The program is …
Read more on PR Web (press release)

Clarifying the Use of Ruxolitinib in Patients With Myelofibrosis
Ruxolitinib (Jakafi) is the first-in-class and only JAK inhibitor currently approved by the US Food and Drug Administration (FDA) for the treatment of patients with MF ; approval was based on the results of the COMFORT (COntrolled MyeloFibrosis study …
Read more on Cancer Network